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Chemokine CXCL13 mediates orofacial
neuropathic pain via CXCR5/ERK pathway
in the trigeminal ganglion of mice
Qian Zhang1†, De-Li Cao1†, Zhi-Jun Zhang1,2, Bao-Chun Jiang1 and Yong-Jing Gao1,3*
Abstract
Background: Trigeminal nerve damage-induced neuropathic pain is a severely debilitating chronic orofacial pain
syndrome. Spinal chemokine CXCL13 and its receptor CXCR5 were recently demonstrated to play a pivotal role in
the pathogenesis of spinal nerve ligation-induced neuropathic pain. Whether and how CXCL13/CXCR5 in the
trigeminal ganglion (TG) mediates orofacial pain are unknown.
Methods: The partial infraorbital nerve ligation (pIONL) was used to induce trigeminal neuropathic pain in mice.
The expression of ATF3, CXCL13, CXCR5, and phosphorylated extracellular signal-regulated kinase (pERK) in the TG
was detected by immunofluorescence staining and western blot. The effect of shRNA targeting on CXCL13 or
CXCR5 on pain hypersensitivity was checked by behavioral testing.
Results: pIONL induced persistent mechanical allodynia and increased the expression of ATF3, CXCL13, and CXCR5 in
the TG. Inhibition of CXCL13 or CXCR5 by shRNA lentivirus attenuated pIONL-induced mechanical allodynia. Additionally,
pIONL-induced neuropathic pain and the activation of ERK in the TG were reduced in Cxcr5−/− mice. Furthermore, MEK
inhibitor (PD98059) attenuated mechanical allodynia and reduced TNF-α and IL-1β upregulation induced by pIONL. TNF-α
inhibitor (Etanercept) and IL-1β inhibitor (Diacerein) attenuated pIONL-induced orofacial pain. Finally, intra-TG injection of
CXCL13 induced mechanical allodynia, increased the activation of ERK and the production of TNF-α and IL-1β in the TG
of WT mice, but not in Cxcr5−/− mice. Pretreatment with PD98059, Etanercept, or Diacerein partially blocked CXCL13-
induced mechanical allodynia, and PD98059 also reduced CXCL13-induced TNF-α and IL-1β upregulation.
Conclusions: CXCL13 and CXCR5 contribute to orofacial pain via ERK-mediated proinflammatory cytokines production.
Targeting CXCL13/CXCR5/ERK/TNF-α and IL-1β pathway in the trigeminal ganglion may offer effective treatment for
orofacial neuropathic pain.
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Background
Chronic neuropathic pain of orofacial region resulting from
nerve trauma, compression, and/or demyelination is debili-
tating and often refractory to treatment. Neuroinflamma-
tion has been demonstrated to play an important role in
the pathogenesis of neuropathic pain [1, 2]. A critical role
in mechanisms of neuroinflammation is attributed to in-
flammatory mediators, including proinflammatory cytokines
and chemokines, which augment the nociceptive signals at
different anatomical locations, including peripheral nervous
system and central nervous system (CNS) [1, 2]. Chemo-
kines are a family of functionally related small secreted
molecules with the established roles in the modulation of
peripheral immune cell trafficking [3]. Increasing evidence
has implicated spinal chemokines in chronic pain processing
following nerve injury [4, 5]. However, little is known about
chemokines in the trigeminal ganglion (TG) in mediating
orofacial neuropathic pain.
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C-X-C motif chemokine 13 (CXCL13), also known as B
lymphocyte chemoattractant, was originally identified in
stromal cells in B cell follicles to regulate homing of B
cells and subsets of T cells [6, 7]. Previous studies showed
that CXCL13 was not expressed in the healthy CNS but
upregulated in the brain and spinal cord under some
pathological conditions [8–10]. However, we recently
found that CXCL13 was highly expressed in the lymph
node and had low expression in the spinal cord of non-
diseased humans [11]. CXCL13 was also expressed in the
spinal cord of naïve mice and was upregulated after spinal
nerve ligation (SNL) [11]. Cxcl13 mRNA was also in-
creased in the dorsal root ganglion (DRG) after DRG local
inflammation or peripheral nerve injury [12].
The biological effects of chemokines are mediated via
interaction with its G protein-coupled receptor (GPCR),
and CXCR5 is the primary receptor of CXCL13. CXCR5 is
expressed on all B cells and a subset of T cells in blood,
lymphatic tissue, and cerebrospinal fluid [13, 14]. We re-
cently found that CXCR5 was expressed in astrocytes in
the spinal cord, and intrathecal injection of CXCL13 in-
duced CXCR5-dependent pain hypersensitivity. Moreover,
SNL-induced neuropathic pain was abrogated in Cxcr5−/−
mice [11], indicating the important role of CXCL13/
CXCR5 signaling in the spinal cord in mediating neuro-
pathic pain.
Mitogen-activated protein kinase (MAPK), including
extracellular signal-regulated kinase 1/2 (ERK1/2), p38,
and c-Jun N-terminal kinase (JNK) can be activated in
the DRG and spinal cord by peripheral nerve injury [15].
Particularly, intrathecal injection of CXCL13 induced
ERK activation in the spinal cord, and SNL-induced
ERK activation was reduced in Cxcr5−/− mice [11], sug-
gesting that ERK is one of the downstream of CXCL13/
CXCR5 signaling. Whether ERK can be activated by
CXCL13/CXCR5 in the TG remains to be investigated.
The TG is a crucial site for pain transmission and pain
modulation from the peripheral to the CNS in the oral
maxillofacial region [16]. In the present study, we used
partial infraorbital nerve ligation (pIONL) model to induce
orofacial pain. We found that pIONL increased CXCL13
and CXCR5 expression in TG neurons, and CXCL13/
CXCR5 was involved in orofacial mechanical allodynia.
Our results also demonstrated that CXCL13/CXCR5 in-
duces ERK activation and further augments neuroinflam-
mation by increasing TNF-α and IL-1β in the TG.
Methods
Animals
Adult ICR mice (male, 8 weeks) were purchased from
Experimental Animal Center of Nantong University.
Cxcr5−/− mice [B6.129S2 (Cg)-Cxcr5tm1Lipp/J, stock num-
ber 006659] were purchased from the Jackson Labora-
tory, and C57BL/6 wild-type mice were used as control.
The animals were maintained on a 12:12 light–dark
cycle at a room temperature of 22 ± 1 °C with free access
to food and water. All animal procedures performed in
this study were reviewed and approved by the Animal
Care and Use Committee of Nantong University and
were conducted in accordance with the guidelines of the
International Association for the Study of Pain. Mice
underwent a modified pIONL. In brief, the mouse was
anesthetized with sodium pentobarbital and laid on the
back. The oral cavity was exposed. A 1-mm longitudinal
incision on the left buccal mucosa and at the level of the
maxillary first molar was made to expose the infraorbital
nerve (ION). The ION was then isolated and approxi-
mately one half of the nerve was tightly ligated with 8-0
silk suture and then transected just distal to the ligature.
The buccal mucosa tissue was then sutured. The surgical
procedure for the sham group was identical to that of
the pIONL group, except that the ION was not ligated
or transected.
Behavioral testing
Animals were habituated to the testing environment
daily for at least 2 days before baseline testing. All the
behavioral experiments were done by individuals that
were blinded to the treatment or genotypes of the mice.
Orofacial operant behavioral assessment
An Orofacial Stimulation Test (31300-002, Ugo Basile,
Comerio VA, Italy) was used for the measurement of
hypersensitivity to the mechanical stimulation of the tri-
geminal area [17, 18]. The apparatus consists of two parts:
the plastic cage with the interface wall containing a drink-
ing window, an infrared photo beam built on the exterior
aspect of the window linked to the ORO software. The
drinking window allows the mouse head to enter and ac-
quire a reward (30 % milk), but the animal will be stimu-
lated by a set of tungsten wire filaments attached around
the drinking window. The animals initially underwent
seven sessions of adaptation trainings in 1 a week without
mechanical stimulator attached. For each training session,
animals were first fasted for a 12-h period. Each mouse
was then placed in a cage in which there was an Orofacial
Stimulation Test System. During the test, the mouse was
given 10 min to familiarize itself with its environment,
and the drinking window was opened and the testing
mouse was subsequently timed for 10 min to allow drink-
ing the milk. The contact number and total duration of
time the mouse spent acquiring the reward were recorded
and analyzed with the ORO software.
Von Frey test
For experiments that several time points are needed to
be checked in 24 h, Von Frey test was used, as orofacial
stimulation test can be checked only once a day. For the
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Von Frey test, the mice were put in metal mesh boxes and
allowed 30 min for habituation before examination. A
graded series of Von Frey filaments was used for mechan-
ical stimulation of the ipsilateral infraorbital nerve territory
(0.02–2.56 g, Stoelting, Wood Dale, IL). The threshold was
taken with a response of a brisk withdrawal of the head.
The 50 % head withdrawal threshold was determined using
Dixon’s up-down method [19].
Drugs and administration
Recombinant murine CXCL13 was purchased from Pepro-
Tech (Rocky Hills, NJ). MEK inhibitor PD98059 was pur-
chased from Merck KGaA (Darmstadt, Germany). TNF-α
inhibitor (Etanercept) and IL-1β inhibitor (Diacerein) were
purchased from Pfizer (New York, NY) and Selleck Chemi-
cals (Westlake Village, CA), respectively. The drugs were
injected with a 30 G needle from the infraorbital foramen to
the foramen rotundum. The tip of the needle terminated at
the medial part of the trigeminal ganglion, and the reagents
(5 μl) was slowly delivered to the trigeminal ganglion [20].
Real-time quantitative PCR (qPCR)
The total RNA of the TG was extracted using Trizol
reagent (Invitrogen). One microgram of total RNA was re-
verse transcribed using an oligo(dT) primer according to
the manufacturer’s protocol (Takara, Shiga, Japan). qPCR
analysis was performed in the Real-time Detection System
(Rotor-Gene 6000, Hamburg, Germany) by SYBR green I
dye detection (Takara). The following primers were used:
Cxcl13 forward, 5′-GGC CAC GGT ATT CTG GAA GC-
3′; Cxcl13 reverse, 5′-ACC GAC AAC AGT TGA AAT
CAC TC-3′; Cxcr5 forward, 5′-TGG CCT TCTA CAG
TAA CAG CA-3′; Cxcr5 reverse, 5′-GCA TGA ATA
CCG CCT TAA AGG AC-3′; Tnf-α forward, 5′-GTT
CTA TGG CCC AGA CCC TCA C-3′; Tnf-α reverse, 5′-
GGC ACC ACTAGT TGG TTG TCT TTG-3′; Il-1β for-
ward, 5′-TCC AGG ATG AGG ACA TGA GCA C-3′; Il-
1β reverse 5′-GAA CGT CAC ACA CCA GCA GGT TA-
3′; Gapdh forward, 5′-GCT TGA AGG TGT TGC CCT
CAG-3′; Gapdh reverse, 5′-AGA AGC CAG CGT TCA
CCA GAC-3′. The PCR amplifications were performed at
95 °C for 30 s, followed by 40 cycles of thermal cycling at
95 °C for 5 s and 60 °C for 45 s. Gapdh was used as
endogenous control to normalize differences. Melt curves
were performed on completion of the cycles to ensure that
nonspecific products were absent. Quantification was
performed by normalizing Ct (cycle threshold) values with
Gapdh Ct and analyzed with the 2-ΔΔCT method.
Western blot
Animals were transcardially perfused with PBS. The ipsi-
lateral trigeminal ganglia were dissected and homogenized
in a lysis buffer containing protease and phosphatase in-
hibitors (Sigma, St Louis, MO). Protein concentrations
were determined by BCA Protein Assay (Pierce, Rockford,
IL). Protein samples (30 μg) were separated on SDS–
PAGE gel and transferred to nitrocellulose blots. The blots
were blocked with 5 % milk and incubated overnight at 4 °
C with antibody against CXCL13 (Goat, 1:100, Santa Cruz,
Dallas, Texas), CXCR5 (rabbit, 1:100, Santa Cruz), pERK
(rabbit, 1:500, Cell Signaling, Beverly, MA), ERK (rabbit,
1:500, Cell Signaling), and GAPDH (mouse, 1:20000,
Millipore, Billerica, MA). These blots were further incu-
bated with IRDye 800CW secondary antibodies for 2 h at
room temperature and captured by Odyssey Imaging
System (LI-COR Bioscience, Lincoln, NE). Specific bands
were evaluated by apparent molecular size. The intensity
of the selected bands was analyzed using Image J software
(NIH, Bethesda, MD).
Immunohistochemistry
Animals were deeply anesthetized with isoflurane and per-
fused through the ascending aorta with PBS followed by 4 %
paraformaldehyde in 0.1M PB. After the perfusion, the
ipsilateral TG was removed, postfixed, and cryo-protected
by 20 % sucrose. TG sections (14 μm) were cut in a cryostat
and processed for immunofluorescence as we described
previously [21]. The sections were first blocked with 8 %
goat or donkey serum for 2 h at room temperature, then in-
cubated overnight at 4 °C with the following primary anti-
bodies: ATF3 (Rabbit, 1:1000, Santa Cruz), CXCL13 (goat,
1:100, Santa Cruz), CXCR5 (rabbit, 1:100; Santa Cruz), neur-
onal specific marker β-III tubulin (Mouse, 1:500, R&D), and
pERK (rabbit, 1:500, Millipore). The sections were then in-
cubated for 2 h at room temperature with Cy3-conjugated
secondary antibodies or Alexa 488-conjugated secondary
antibodies (1:1000, Jackson ImmunoResearch, West Grove,
PA). The stained sections were examined with a Leica fluor-
escence microscope, and images were captured with a CCD
Spot camera. The specificity of the CXCL13 antibody and
CXCR5 antibody were checked by absorption experiment or
in Cxcr5 KO mice, respectively [11].
Lentiviral vectors production and intra-TG injection
The shRNA targeting the sequence of mice Cxcl13 (Gene
Bank Accession: NM_018866) or Cxcr5 (Gene Bank Acces-
sion: NM_007551) was designed respectively. An additional
scrambled sequence was also designed as a negative control
(NC). The recombinant lentivirus containing Cxcl13 shRNA
(LV-Cxcl13 shRNA), Cxcr5 shRNA (LV-Cxcr5 shRNA), or
NC shRNA (LV-NC) was packaged using pGCSIL-GFP
vector by GeneChem (Shanghai, China). The sequences of
the shRNAs are: Cxcl13 shRNA, 5′-TCG TGC CAA ATG
GTT ACA A-3′; Cxcr5 shRNA, 5′-CCA TCA CCT TGT
GTG AAT T-3′; NC shRNA, and 5′-TTC TCC GAA CGT
GTC ACG T-3′. The lentivirus (8 × 105 TU, 1 μl) was
injected into the trigeminal ganglion through the infraorbital
foramen using a 30 G needle.
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Quantification and statistics
All data were expressed as mean ± SEM. The behavioral
data were analyzed by two-way repeated measures
ANOVA followed by Bonferroni test as the post hoc mul-
tiple comparison analysis. For Western blot, the density of
specific bands was measured with ImageJ. CXCL13 and
CXCR5 levels were normalized to GAPDH, and pERK
levels were normalized to total ERK [22]. Differences be-
tween groups were compared using one-way ANOVA
followed by Bonferroni test or using Student’s t test if only
two groups were applied. The criterion for statistical sig-
nificance was P < 0.05.
Results
pIONL induces persistent mechanical allodynia and ATF3
expression in the TG
Before and after pIONL or sham operation, we performed
orofacial operant tests to check mechanical allodynia. Both
total contact number and contact time were recorded and
analyzed. As shown in Fig. 1a, total contact number was
not significantly changed after pIONL, and no significant
difference was found between sham and pIONL groups
(P > 0.05, two-way repeated measures ANOVA). However,
total contact time in pIONL group was reduced 1 day after
the operation, maintained from day 3 to day 14, began to
Fig. 1 pIONL induces mechanical allodynia assessed by orofacial operant test and increases ATF3 expression in the maxillary division of TG neurons.
a Total contact number of orofacial operant test with mechanical stimulation was comparable between sham and pIONL mice. P> 0.05. Two-way repeated
measures ANOVA. b Total contact time was significantly decreased from 1 to 21 days after pIONL, compared to sham group. **P< 0.01, ***P< 0.001, pIONL
vs. sham. Two-way repeated measures ANOVA followed by Bonferroni test. c The percentage of ATF3-positive cells were dramatically increased in the
maxillary division (V2) of TG 10 days after pIONL, whereas ATF3-positive cells were not significantly changed in the ophthalmic (V1) division or mandibular
(V3) division. ***P< 0.001, pIONL vs. sham. Student’s t test. d–g Representative images show the expression of ATF3 in the TG of sham-treated (d, e) or
pIONL (f, g) animals. e, g High-magnification images of d and f, indicated in the white boxes
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recover toward baseline at day 21 and fully recovered at
day 28 (P < 0.001, two-way repeated measures ANOVA),
whereas the sham-operated animals showed similar contact
time during all the time points (P > 0.05, two-way repeated
measures ANOVA, Fig. 1b). These data indicate that the
reduction of total contact time in pIONL group is not due
to the decrease of animals’ attempt to drink milk [23]. In
addition, the time course of pIONL-induced mechanical
allodynia reflected by the reduction of contact time is com-
parable to the test by Von Frey filaments [24], suggesting
that orofacial operant test is reliable, and pIONL induces
persistent mechanical allodynia.
We then checked the expression of ATF3, a marker for
nerve injury in the ipsilateral TG 10 days after operation.
ATF3-immunoreactivity (IR) was not shown in the TG of
sham-operated mice (Fig. 1c–e). However, pIONL dramat-
ically increased the percentage of ATF3-IR neurons in the
maxillary (V2) division of TG from 0.5 ± 0.1 to 49.8 ±
0.7 % (P < 0.001, Fig. 2c, f, g). The percentage of ATF3-IR
cells was not significantly changed in the ophthalmic (V1)
division or mandibular (V3) division (P > 0.05, pIONL vs.
sham, Fig. 1c). These data confirmed the injury of the sec-
ond branch of the trigeminal nerve by pIONL.
pIONL induces persistent CXCL13 upregulation in the TG
We then checked the expression of Cxcl13 in the ipsilateral
TG after pIONL or sham-operation. Cxcl13 mRNA was
significantly increased at days 1, 10, and 21 in pIONL mice
compared to sham-operated mice (P < 0.05 or 0.001,
pIONL vs. sham, two-way ANOVA followed by Bonferroni
test, Fig. 2a). The mRNA level did not significantly differ
between naïve and sham-operated mice at all the time
points (P > 0.05, one-way ANOVA, Fig. 2a). We further
checked CXCL13 protein level by western blot. As shown
in Fig. 2b, pIONL significantly increased CXCL13 protein
compared to sham operation (P < 0.05, Student’s t test).
Fig. 2 pIONL induces persistent CXCL13 expression in the TG. a The time course of Cxcl13 mRNA expression in the ipsilateral TG from naïve, sham, and
pIONL-operated mice. pIONL increased Cxcl13 expression at 3, 10, and 21 days, compared to sham. *P< 0.05, ***P< 0.001. Two-way ANOVA followed by
Bonferroni test. bWestern blot shows increased CXCL13 protein level 10 days after pIONL, compared to sham. *P< 0.05. Student’s t test. c Representative
images of CXCL13 immunofluorescence in the TG. CXCL13-IR was low in naïve mice (c) and sham mice (d), but increased in the TG of pIONL mice
(e). f–h Double staining of CXCL13 (f) and neuronal marker β-III tubulin (g) shows the neuronal expression of CXCL13
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Immunostaining further showed that CXCL13 was
expressed in the TG of naïve animals (Fig. 2c) and sham-
operated animals (Fig. 2d). pIONL markedly increased
CXCL13 expression 10 days after operation (Fig. 2e).
Double staining of CXCL13 with neuronal marker β-III
tubulin showed that CXCL13 was expressed in neurons
(Fig. 2f–h). These data suggest the possible involvement of
CXCL13 in pIONL-induced orofacial pain.
Inhibition of CXCL13 by shRNA lentivirus alleviates pIONL-
induced mechanical allodynia
To examine the role of CXCL13 in the development and
maintenance of trigeminal neuropathic pain, we injected
Cxcl13 shRNA lentivirus vectors (LV-Cxcl13 shRNA) into
the TG before or after pIONL. Our previous study has
shown that LV-Cxcl13 shRNA effectively decreased
CXCL13 expression both in vitro and in vivo [11]. As
shown in Fig. 3a, compared to control lentivirus injection
(LV-NC), pretreatment with LV-Cxcl13 shRNA (7 days
before pIONL) inhibited pIONL-induced mechanical allo-
dynia for more than 21 days (P < 0.001, two-way repeated
measures ANOVA). In addition, posttreatment with LV-
Cxcl13 shRNA (3 days after pIONL) also attenuated
mechanical allodynia from day 7 to day 14 (P < 0.001, two-
way repeated measures ANOVA, Fig. 3b). These data
suggest that CXCL13 plays an important role in both de-
velopment and maintenance of trigeminal neuropathic
pain.
To confirm the knockdown effect of LV-Cxcl13 shRNA,
we checked green fluorescent protein (GFP) expression
7 days after the injection and found GFP fluorescence in
the maxillary division of TG (Fig. 3c). In addition, pre-
treatment of LV-Cxcl13 shRNA inhibited pIONL-induced
Cxcl13 mRNA increase 10 days after pIONL (P < 0.01, vs.
LV-NC), whereas LV-NC had no effect on Cxcl13 expres-
sion (P > 0.05, vs. pIONL, Fig. 3d).
pIONL induces persistent CXCR5 upregulation in the TG
CXCR5 was reported to be the sole receptor for CXCL13
[25]. We then checked the time course of Cxcr5 mRNA
expression in the TG. pIONL induced persistent Cxcr5
mRNA upregulation, which started at day 3 and maintained
at day 21 (P < 0.05 or 0.01, pIONL vs. sham, two-way
ANOVA followed by Bonferroni test, Fig. 4a). Western blot
Fig. 3 Inhibition of CXCL13 by shRNA lentivirus attenuated pIONL-induced mechanical allodynia. a Pretreatment with LV-Cxcl13 shRNA increased
the contact time between 3 and 21 days after the operation, compared to LV-NC-injected mice. Intra-TG injection was performed 7 days before
pIONL (arrow). *P < 0.05, **P < 0.01, ***P < 0.001. Two-way repeated measures ANOVA followed by Bonferroni test. b Posttreatment with LV-Cxcl13
shRNA increased the contact time between 7 and 14 days after the operation, compared to LV-NC treatment. Intra-TG injection was performed
3 days after pIONL (arrow). *P < 0.05, **P < 0.01. Two-way repeated measures ANOVA followed by Bonferroni test. c Representative fluorescence
photomicrograph shows GFP expression in the TG 7 days after intra-TG infusion of lentivirus vector. d Real-time PCR assay of Cxcl13 shows that
pretreatment with LV-Cxcl13 shRNA inhibited pIONL-induced Cxcl13 upregulation. **P < 0.01, ***P < 0.001. Student’s t test
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showed that CXCR5 protein level was significantly in-
creased in pIONL mice at 10 days (P < 0.05, pIONL vs.
sham or naive, one-way ANOVA followed by Bonferroni
test, Fig. 4b). Immunostaining further revealed that CXCR5
had low expression in the TG in naïve mice (Fig. 4c) and
sham-operated mice (Fig. 4d). CXCR5-IR was markedly in-
creased 10 days after pIONL (Fig. 4e). In addition, CXCR5
was highly colocalized with β-III tubulin (Fig. 4f–h), indi-
cating the neuronal expression of CXCR5 in the TG.
Deletion of CXCR5 or inhibition of CXCR5 by shRNA
lentivirus reduces pIONL-induced mechanical allodynia
To determine the role of CXCR5 in trigeminal neuropathic
pain, we checked pain behaviors in wild-type (WT; C57Bl/
6) mice and Cxcr5−/− (KO) mice. Acute mechanical sensi-
tivity, as evaluated by Von Frey filament (Fig. 5a) was com-
parable between the two genotypes (P > 0.05, Student’s t
test). We then tested mechanical allodynia by orofacial
operant behavioral assessment after pIONL. pIONL-
induced mechanical allodynia was significantly reduced at
days 3, 7, 10, and 14 in Cxcr5 KO mice compared to WT
mice (P < 0.001, two-way repeated measures ANOVA,
Fig. 5b)
To further check the role of CXCR5 in maxillary division
of TG in the pathogenesis of neuropathic pain, we injected
Cxcr5 shRNA lentivirus (LV-Cxcr5 shRNA and LV-NC)
into the TG 10 days before or 3 days after pIONL in ICR
mice. Pretreatment with LV-Cxcr5 shRNA blocked pIONL-
induced mechanical allodynia from 3 to 21 days after
pIONL (P < 0.001, two-way repeated measures ANOVA,
Fig.5c). Posttreatment with LV-Cxcr5 shRNA alleviated
mechanical allodynia from day 7 to day 21 (P < 0.001, two-
way repeated measures ANOVA, Fig. 5d). qPCR further
confirmed the knockdown effect of LV-Cxcr5 shRNA on
the expression of Cxcr5 mRNA (P < 0.05, LV-Cxcr5 shRNA
vs. LV-NC, Fig. 5e).
Fig. 4 pIONL induces persistent CXCR5 expression in the TG. a The time course of Cxcr5 mRNA expression in the ipsilateral TG from naïve, sham,
and pIONL-operated mice. pIONL increased Cxcr5 expression at 3, 10, and 21 days, compared to sham. *P < 0.05, **P < 0.01. Two-way ANOVA followed
by Bonferroni test. b Western blot shows increased CXCR5 protein level 10 days after pIONL, compared to sham. *P < 0.05. One-way ANOVA followed
by Bonferroni test. c Representative images of CXCR5 immunofluorescence in the TG. CXCR5-IR was low in naïve mice (c) and sham mice (d), but
increased in the TG of pIONL mice (e). f–h Double staining of CXCR5 (f) and neuronal marker β-III tubulin (g) shows the neuronal expression of CXCR5
Zhang et al. Journal of Neuroinflammation  (2016) 13:183 Page 7 of 13
pIONL induces ERK activation in the TG of WT mice
Our recent study showed that ERK is an important down-
stream of CXCL13/CXCR5 signaling in the spinal cord
[11]. We then checked the activation of ERK in the TG
after pIONL. Western blot showed that, compared to
naive or sham-operated animals, pIONL increased pERK
expression in the TG 10 days after pIONL (P < 0.05, vs.
naïve or sham, one-way ANOVA followed by Bonferroni
test, Fig. 6a). In addition, pERK expression was comparable
between WT and Cxcr5 KO mice after sham operation,
but pERK was significantly reduced in KO mice after
pIONL (P < 0.05, vs. WT, Student’s t test). Immunostaining
showed that pERK had low expression in WT mice after
sham operation, but was increased in WT mice after
pIONL. However, similar expression of pERK was ob-
served in both sham-operated and pIONL KO mice
(Fig. 6b).
pIONL-induced mechanical allodynia is mediated by
ERK-dependent proinflammatory cytokines production
in the TG
We further checked the downstream of ERK underlying
pIONL-induced orofacial mechanical allodynia. TNF-α
and IL-1β are important proinflammatory cytokines in
regulating chronic pain in both peripheral nervous
system and central nervous system [26]. We checked
TNF-α and IL-1β mRNA expression in the TG 10 days
after pIONL or sham operation. As shown in Fig. 7a,
pIONL increased TNF-α and IL-1β mRNA expression in
the TG of WT mice (TNF-α, P < 0.05; IL-1β, P < 0.001,
pIONL vs. sham), but not in KO mice. These data sug-
gest that pIONL induces CXCR5-dependent TNF-α and
IL-1β expression.
To assess whether the production of TNF-α and IL-1β is
dependent on ERK pathway, we injected MEK inhibitor
PD98059 into the TG 10 days after pIONL. PD98059
(10 μg) [27] attenuated pIONL-induced mechanical allody-
nia 3 h after injection (P < 0.01, two-way repeated measures
ANOVA, Fig. 7b) and reduced TNF-α and IL-1β mRNA ex-
pression (P < 0.01, PD98059 vs. vehicle, Fig. 7c, d), indicating
that TNF-α and IL-1β are the downstream of ERK pathway
in the TG.
We then checked the analgesic effect of the TNF-α in-
hibitor (Etanercept) and IL-1β inhibitor (Diacerein) on
pIONL-induced mechanical allodynia. Intra-TG injection
of Etanercept (1 μg) [21] 10 days after pIONL significantly
Fig. 5 CXCR5 is essential for pIONL-induced mechanical allodynia. a Mechanical sensitivity assessed by Von Frey test was indistinguishable in WT and KO
mice. b pIONL-induced mechanical allodynia was significantly reduced in Cxcr5 KO mice, compared to WT mice. *P< 0.05, **P< 0.01. Two-way repeated
measures ANOVA followed by Bonferroni test. c Pretreatment with LV-Cxcr5 shRNA increased the contact time between 3 and 21 days after the operation,
compared to LV-NC-injected mice. *P< 0.05, ***P< 0.001. Two-way repeated measures ANOVA followed by Bonferroni test. d Posttreatment with LV-Cxcr5
shRNA increased the contact time between 7 and 21 days after the operation, compared to LV-NC treatment. *P< 0.05, **P< 0.01, ***P< 0.001. Two-way
repeated measures ANOVA followed by Bonferroni test. e Real-time PCR assay of Cxcr5 shows that pretreatment with LV-Cxcr5 shRNA inhibited
pIONL-induced Cxcr5 upregulation. *P< 0.05, **P< 0.01, ***P< 0.001. Student’s t test
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alleviated pIONL-induced mechanical allodynia, with the
effect maintained for more than 6 h (P < 0.001, two-way
repeated measures ANOVA, Fig. 7e). Similarly, intra-TG
injection of Diacerein (5 μg) [28] also attenuated pIONL-
induced mechanical allodynia at 1, 3, and 6 h (P < 0.001,
two-way repeated measures ANOVA, Fig. 7f). These re-
sults suggest that proinflammatory cytokines TNF-α and
IL-1β are important in mediating orofacial neuropathic
pain.
Intra-TG injection of CXCL13 induces CXCR5/ERK-dependent
mechanical allodynia and proinflammatory cytokines
production
To investigate whether CXCL13 is sufficient to induce
orofacial pain, we injected CXCL13 into the TG in WT
and Cxcr5 KO mice. As shown in Fig. 8a, CXCL13
(100 ng), but not vehicle (PBS)-induced mechanical allo-
dynia in WT mice for more than 6 h (P < 0.001, two-way
repeated measures ANOVA), whereas Cxcr5 KO mice
failed to develop the mechanical allodynia by CXCL13
(Fig. 8b).
We further checked the expression of pERK in the TG
after CXCL13 injection. Western blot showed that
CXCL13 induced significant pERK expression in the TG
1 h after injection in WT mice (P < 0.05, Student’s t test),
but not in Cxcr5 KO mice (P > 0.05, Student’s t test,
Fig. 8c). These data suggest that ERK is the downstream
of CXCL13/CXCR5 signaling in the TG.
To examine whether CXCL13 could increase TNF-α
and IL-1β mRNA expression in the TG, we checked the
mRNA level of TNF-α and IL-1β in the TG 1 and 3 h
after CXCL13 injection. It showed that the expression of
TNF-α and IL-1β mRNA was significantly increased at
both 1 and 3 h in the WT mice (P < 0.01, one-way
ANOVA, Fig. 8d). However, the mRNA level of TNF-α
and IL-1β was not significantly changed in Cxcr5 KO
mice (P > 0.05, one-way ANOVA, Fig. 8d), suggesting
that CXCL13-induced TNF-α and IL-1β expression is
dependent on CXCR5.
To check if CXCL13-induced mechanical allodynia is
dependent on ERK activation and TNF-α and IL-1β pro-
duction, PD98059, Etanercept, or Diacerein was injected
into the TG and followed by CXCL13 injection 1 h later.
Behavioral test showed that pretreatment with these drugs
partially attenuated CXCL13-induced mechanical allodynia
(P < 0.001, two-way repeated measures ANOVA, Fig. 8e).
In addition, PD98059 pretreatment also reduced the mRNA
level of TNF-α (1 ± 0.27 vs. 0.27 ± 0.09, vehicle + CXCL13
vs. PD98059 +CXCL13, P < 0.05, Student’s t test) and IL-1β
(1 ± 0.23 vs. 0.31 ± 0.06, vehicle + CXCL13 vs. PD98059 +
CXCL13, P < 0.05, Student’s t test), which was examined
3 h after CXCL13 injection. These data indicate that
CXCL13-induced mechanical allodynia is dependent on
CXCR5/ERK/TNFα and IL-1β pathway.
Discussion
This is the first study that examines in detail the role of
CXCL13/CXCR5 signaling in the maxillary part of the
TG in pIONL-induced mechanical allodynia. We have
made the following new findings. First, pIONL persist-
ently increased CXCL13 and CXCR5 expression in TG
neurons. Consistently, inhibition of CXCL13/CXCR5
before or after pIONL attenuated pIONL-induced mech-
anical allodynia. Second, pIONL induced ERK activation
Fig. 6 pIONL induces the activation of ERK in the TG. a Western blot shows the expression of pERK in naive, sham, and pIONL mice. pIONL increased
the expression of pERK expression in WT mice, and the increase was reduced in Cxcr5 KO mice. *P < 0.05. One-way ANOVA followed by Bonferroni test
(left histogram) or Student’s t test (right histogram). b Representative images of pERK immunofluorescence in the TG of WT and KO mice 10 days after
the operation. pERK-IR was increased after pIONL in WT mice, but not in KO mice
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and ERK-dependent TNF-α and IL-1β production in the
TG of WT mice. TNF inhibitor and IL-1 inhibitor alleviated
pIONL-induced mechanical allodynia. Finally, intra-TG in-
jection of CXCL13 induced mechanical allodynia, ERK acti-
vation, and TNF-α and IL-1β production. Inhibition of ERK
signaling or TNF-α or IL-1β attenuated CXCL13-induced
mechanical allodynia. Taken together, our results indicate
that CXCL13/CXCR5 signaling in the TG is involved in oro-
facial neuropathic pain, at least partially, via ERK-mediated
proinflammatory cytokines production.
CXCL13 upregulation in the TG contributes to neuropathic
pain
Chemokines, which comprise a family of >50 family mem-
bers, have been recognized for its pivotal role in the patho-
genesis of neuropathic pain [2, 29, 30]. Several chemokines
including CCL2, CCL7, and CXCL1 are upregulated in the
spinal cord following nerve injury and contribute to neuro-
pathic pain [21, 31, 32]. By using mouse gene expression
microarrays, we recently found that 10 chemokines (includ-
ing CCL2, CCL7, CXCL1, and CXCL13) whose expression
was increased more than three fold in the spinal cord after
SNL. Among them, CXCL13 is the most upregulated gene
with 47-fold increase [11]. In the present study, we for the
first time found that CXCL13 mRNA in the TG was upreg-
ulated 3 days after ligation and maintained for more than
21 days. Western blot and immunostaining further showed
the upregulated CXCL13 protein in the ipsilateral TG. In
agreement with our results, Strong et al. reported that
CXCL13 mRNA was increased in the DRG 14 days after
local inflammation of DRG or 3 days after SNL or modified
SNL model in rats [12]. Previous studies have shown that
CXCL13 was induced in some microglia, macrophages, and
endothelial cells in the CNS after infection [33, 34] or in
infiltrating dendritic cells in EAE mice [8, 9]. Our recent
data showed that CXCL13 was predominantly produced by
spinal neurons after SNL [14]. Here, we also found that
CXCL13 was expressed in TG neurons, indicating the
Fig. 7 pIONL-induced mechanical allodynia is mediated by ERK-dependent proinflammatory cytokines production in the TG. a pIONL increased TNF-α
and IL-1β expression 10 days after pIONL in WT mice, but not in Cxcr5 KO mice. *P< 0.05, ***P< 0.001. One-way ANOVA followed by Bonferroni test.
b Intra-TG injection of MEK inhibitor, PD98059 10 days after pIONL attenuated pIONL-induced mechanical allodynia at 3 h. **P< 0.01. Two-way repeated
measures ANOVA followed by Bonferroni test. The same treatment reduced the expression of TNF-α (c) and IL-1β (d). **P< 0.01, Student’s t test. e Intra-TG
injection of TNF-α inhibitor, Etanercept 10 days after pIONL alleviated pIONL-induced mechanical allodynia. The effect was shown 1 h after injection and
maintained for more than 6 h. *P< 0.05, ***P< 0.001. Two-way repeated measures ANOVA followed by Bonferroni test. f Intra-TG injection of IL-1β inhibitor,
Diacerein 10 days after pIONL alleviated pIONL-induced mechanical allodynia from 1 to 6 h. *P< 0.05, ***P< 0.001. Two-way repeated measures ANOVA
followed by Bonferroni test
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neuronal expression of CXCL13 in both TG and spinal
cord.
By using shRNA lentivirus injection to specific knock-
down the expression of CXCL13 in the maxillary part of
the TG, we found that both pretreatment and posttreat-
ment with CXCL13 shRNA lentivirus effectively attenuated
pIONL-induced mechanical allodynia. These data suggest
that CXCL13 is necessary for the development and main-
tenance of orofacial neuropathic pain.
CXCR5 upregulation in the TG contributes to neuropathic
pain
It has been demonstrated that chemokines are involved in
chronic pain modulation through neuronal-glial interac-
tions [5]. For example, chemokines CX3CL1 and CCL21
are expressed in primary sensory neurons and induce
microglial activation via their microglial receptors CX3CR1
and CCR7/CXCR3, respectively [35–38]. Our previous
studies have demonstrated astroglial-neuronal interaction
in neuropathic pain via respective expression of CCL2 and
CXCL1 in spinal astrocytes and CCR2 and CXCR2 in spinal
neurons [21, 31]. We recently reported that CXCR5, the
receptor of CXCL13, was expressed in spinal astrocytes and
mediated a novel form of neuronal-glial interaction in
neuropathic pain [11]. In this study, we found that CXCR5
was persistently (>21 days) increased after pIONL with the
expression in TG neurons, suggesting that CXCL13 and
CXCR5 in the TG mediate orofacial neuropathic pain
through distinct mechanism.
Our behavioral data showed that pIONL-induced mech-
anical allodynia was reduced from 3 to 14 days in Cxcr5-
deficient mice. In addition, using shRNA lentivirus injec-
tion to specific knockdown the expression of CXCR5 in
the maxillary part of the TG, we found that both pretreat-
ment and posttreatment with CXCR5 shRNA lentivirus
effectively attenuated pIONL-induced mechanical allody-
nia. These data suggest that CXCL13/CXCR5 signaling is
necessary for the development and maintenance of orofa-
cial neuropathic pain. Moreover, intra-TG injection of
CXCL13 induced CXCR5-dependent mechanical allodynia
Fig. 8 Intra-TG injection of CXCL13 induces CXCR5/ERK-dependent mechanical allodynia and proinflammatory cytokines production. a, b Intra-TG injection
of CXCL13 (100 ng) induced mechanical allodynia in WT mice (a), but not in Cxcr5 KO mice (b). ***P< 0.001, WT-vehicle vs. WT-CXL13. Two-way repeated
measures ANOVA followed by Bonferroni test. cWestern blot showing that intra-TG CXCL13 significantly increased pERK expression in the TG in WT mice,
but not in Cxcr5 KO mice. *P< 0.05. Student’s t test. d Intra-TG injection of CXCL13 increases TNF-α and IL-1β expression at 1 and 3 h in WT mice, but not
in Cxcr5 KO mice. *P< 0.05, **P< 0.01. One-way ANOVA followed by Bonferroni test. e Intra-TG injection of PD98059, Etanercept, or Diacerein partially
blocked intra-TG CXCL13-induced mechanical allodynia. *P< 0.05, **P< 0.01, ***P< 0.001. Two-way repeated measures ANOVA followed by Bonferroni test
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for more than 6 h, indicating that activation of CXCR5
in the TG is also sufficient to induce orofacial pain
hypersensitivity.
CXCR5-ERK cascade contributes to trigeminal neuropathic
pain
CXCR5 belongs to G protein-coupled receptors (GPCR)
family, and activation of GPCR can regulate many signaling
pathways. MAPKs are key components in GPCR-induced
intracellular signaling [39] and have been implicated in
mediating chronic pain in both DRG and spinal cord [15].
Peripheral inflammation by complete Freund’s adjuvant
(CFA) [40] or nerve injury by SNL [41–43] induces ERK
activation in DRG neurons. In addition, the temporoman-
dibular joint inflammation increases pERK expression in
the TG [44]. Here, we found that pIONL increased pERK
expression in TG neurons of WT mice. However, the
expression of pERK was reduced in Cxcr5-deficient mice.
Moreover, intra-TG injection of CXCL13 induced CXCR5-
dependent pERK upregulation in the TG. Our recent study
showed that CXCL13 activated ERK in spinal astrocytes
through CXCR5 [11]. These data suggest the important role
of ERK in mediating CXCL13/CXCR5 signaling in both TG
and spinal cord.
Studies have shown that intrathecal injection of MEK
inhibitor alleviated CFA-induced inflammatory pain and
peripheral nerve injury-induced neuropathic pain [45, 46].
We showed that intra-TG injection of PD98059 attenuated
pIONL- or CXCL13-induced mechanical allodynia. It was
known that ERK mediates the expression of inflammatory
mediators, including growth factors [45] and proinflamma-
tory cytokines (e.g., IL-1β) [47]. We also found that pIONL
increased TNF-α and IL-1β expression in the TG of WT
mice, but the expressions were reduced in Cxcr5 KO mice.
In addition, intra-TG injection of CXCL13 induced CXCR5/
ERK-dependent TNF-α and IL-1β upregulation. TNF-α and
IL-1β are important proinflammatory cytokines that mediate
chronic pain in both DRG and spinal cord [48]. Behavioral
data further showed that inhibition of TNF-α or IL-1β alle-
viated pIONL- or CXCL13-induced pain hypersensitivity,
indicating the important role of proinflammatory cytokines
in mediating orofacial neuropathic pain.
Conclusions
In this study, we provided the first evidence that CXCL13
and CXCR5 were involved in pIONL-induced orofacial
mechanical allodynia via ERK-mediated proinflammatory
cytokines production in the TG. Thus, targeting the
CXCL13/CXCR5/ERK/TNF-α and IL-1β pathway in the
TG may provide a novel therapeutic approach for the
treatment of the trigeminal neuralgia.
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